|
|
||||||||
Ann Thorac Surg 1997;63:1200-1204
© 1997 The Society of Thoracic Surgeons
Department of Surgery and Division of Infectious Diseases, Jefferson Medical College; and Division of Gastroenterology, John F. Kennedy Hospital, Philadelphia, Pennsylvania
| Abstract |
|---|
|
|
|---|
Methods. Twenty-five cases of Candida pericarditis reported in the last 30 years along with 1 new case were reviewed with regard to demographics, precipitating factors, diagnosis, treatment, and outcome.
Results. The syndrome occurred in immunocompromised (73%), antibiotic-treated (62%), or postpericardiotomy (54%) patients. The clinical presentation was frequently subtle and nonspecific. Nevertheless, unexplained fever, an increasing cardiac shadow on chest roentgenogram, or the development of cardiac tamponade may be suggestive. Positive culture for Candida in pericardial fluid or histologic evidence of yeast forms in pericardial tissue establishes the diagnosis. A combination of pericardiocentesis followed by operative drainage and antifungal agents is the usual treatment. Untreated, Candida pericarditis is 100% lethal, whereas prompt diagnosis and treatment lead to cure (mean follow-up, 19 months).
Conclusions. Fever and evolving cardiac tamponade in immunocompromised or postpericardiotomy patients may be suggestive of Candida pericarditis; the presence of organisms in pericardial fluid is diagnostic. Pericardiocentesis followed by operative drainage and antifungal agents appears to be the treatment that is most likely to be curative.
| Introduction |
|---|
|
|
|---|
As in purulent pericarditis, the clinicopathologic features of Candida pericarditis result from compromised cardiac performance and progressive inflammation. Thus, unless it is recognized early, Candida pericarditis has been shown to cause severe systemic sepsis, cardiac tamponade, and death. To prevent delays in treatment, there is a need to characterize the clinical presentation of this rare disease and to examine therapeutic modalities and results. To that end, we reviewed 25 reported cases along with 1 new case.
| Material and Methods |
|---|
|
|
|---|
| Reviewed Cases |
|---|
|
|
|---|
|
|
|
|
| Case Report |
|---|
|
|
|---|
Postoperatively, the patient had continued fevers despite broad-spectrum antibiotic therapy. All cultures from sterile sites, including the blood, remained negative. However, yeast was isolated from a superficial culture of the thoracoabdominal incision. An upper gastrointestinal series showed no extravasation of contrast material. Meanwhile, antituberculous medications were instituted for caseating granulomas found in the lung biopsy specimen obtained during operation. Nine days after operation, a new cardiac murmur and a pericardial friction rub were noted. On the 15th postoperative day, the patient demonstrated hypotension, jugular venous distention, increased cardiac silhouette on chest roentgenogram, and low voltage in all electrocardiographic leads. A transthoracic echocardiogram confirmed the diagnosis of cardiac tamponade. Ultrasound-guided pericardiocentesis was used to drain 250 mL of serosanguinous fluid, with a dramatic improvement in the shock state. The aspirated fluid had a few white blood cells, but no organisms were seen on routine and fungal stains. Repeat echocardiogram performed 12 hours later demonstrated a large recurrent pericardial effusion. Because of deteriorating hemodynamic status, a subxiphoid pericardial window was performed. Four hundred milliliters of serous fluid was obtained, with an instant elevation of blood pressure and clinical improvement. The postoperative course was unremarkable. Culture of both the aspirated and surgically drained pericardial fluid grew C albicans and the patient was started on amphotericin 0.5 mgkg-1day-1. Histologic examination of the pericardial fluid was negative for fungal elements. The patient was discharged from the hospital in good condition and finished her course of amphotericin, which was continued for a total of 1 g.
Eight months later, the patient died of fulminant non-yeast sepsis secondary to a newly developed tracheobronchial fistula. Autopsy was not performed.
| Comment |
|---|
|
|
|---|
The pathogenesis of Candida pericarditis is still obscure. Nevertheless, several considerations support the possibility that pericardial Candida infection is a form of hematogenously disseminated disease. First, antibiotic therapy, a major predisposing factor for Candida pericarditis, has been shown to promote fungal colonization of various organs, such as the skin [18], airways [18, 19], and urinary tract [20, 21], probably by facilitating superinfection [21, 22]. Second, immunosuppressed conditions such as malignancy [2325] or chronic steroid therapy [26] have been identified to render patients susceptible to Candida infections. Third, nearly half of the patients reviewed in this study had positive Candida cultures in various body fluids (see Table 3
). On the other hand, it is possible that pericardial fungal infection is primarily a local event. This observation is supported by the high percentage of infected patients who had undergone pericardiotomy. Furthermore, most of these patients had additional complicating local factors that could promote pericardial inflammation, such as repeat thoracotomy, pericardial or mediastinal drainage tubes, and open cardiac resuscitation.
Cardiac tamponade, reported in 8 patients (see Table 1
), is probably the only clinical manifestation that can be directly related to Candida pericarditis. Because ultrasound, which has greatly facilitated the diagnosis of cardiac tamponade [27], was not available in the earlier series, it is possible that the incidence of cardiac tamponade in patients with Candida pericarditis was actually higher. The presence of pericardial fluid in 11 patients and of progressively enlarging cardiac silhouette in 10 cases (see Table 1
) strongly supports this assumption.
Most of the patients in the present series had multiple complex medical conditions such as sepsis, major operations, and an extended stay in the intensive care unit (data not shown). Therefore, it is extremely difficult to characterize accurately other clinical manifestations of Candida pericarditis per se. It is impossible, for example, to determine whether the fungal pericardial infection itself can produce a full-blown septic shock. Nevertheless, fever and a newly developed pericardial rub or cardiac murmur seem to be other prominent features of Candida pericarditis (see Table 1
). Although electrocardiographic data were not available in the majority of cases, the most common findings were nonspecific changes with diffuse low voltage. A rapid increase in cardiac silhouette, especially without pulmonary vascular congestion, was the most prominent finding on the chest roentgenogram (reported in 10 patients).
Because the clinical presentation of Candida pericarditis is often nonspecific, prompt diagnosis of this syndrome can be difficult. Indeed, the majority of patients in this review were diagnosed on postmortem examination. In all other patients, ultrasound-guided pericardiocentesis facilitated the diagnosis by yielding a sample of pericardial fluid for microbiologic and histologic analysis (see Table 2
). Isolation of Candida species in cultures from pericardial tissue or fluid and the demonstration of fungal elements on histologic sections, along with evidence of acute inflammation, establish a definitive diagnosis (see Table 2
). Although blood cultures [28] and serologic tests [29] may facilitate the diagnosis of a systemic Candida infection, they do not indicate pericardial involvement.
Treatment of most patients diagnosed while having active disease included a combination of antifungal agents, pericardiocentesis, and operative drainage. Amphotericin B at 0.5 to 1.0 mgkg-1day-1 with a cumulative dose of 1.5 to 2.5 g has been the recommended antifungal agent [30]. The combined administration of amphotericin B with flucytosine has been reported as well [16]. However, none of the patients so far described were treated with the newer antifungal agent fluconazole. Based on its low toxicity, high tissue penetration, and demonstrated efficacy in various candidal infections [31], it may be an option in future cases of Candida pericarditis.
Pericardiocentesis has been shown to produce variable results. In most patients, this procedure provided only temporary relief of both infection and cardiac tamponade, with a rapid recurrence of effusion. Recurrence may be more prominent in patients with thick, loculated effusions, and multiple attempts at aspiration may lead to severe complications. Operative drainage of the pericardial sac is the definitive treatment and can be performed by either a transthoracic or a subxiphoid approach. The latter has the advantage of being performed through a small epigastric incision, as compared with a median sternotomy or a thoracotomy incision. On the other hand, some reports advocate the transthoracic approach when the pericardium is very thickened and tenacious [9]. Unfortunately, because of the limited available data, no definitive conclusion can be drawn regarding the optimal approach for operative drainage of the Candida-infected pericardial sac. Thoracoscopic evacuation can be considered as well.
All patients whose diagnosis was overlooked died of their disease, whereas patients who were diagnosed and treated survived for a mean follow-up of 19 months, with no signs of infection (see Table 4
). Two patients died of unrelated complications after major surgical procedures, and 1 patient died postoperatively of unspecified cause.
To summarize, Candida pericarditis is a rare syndrome that should be suspected in immunocompromised patients in whom fever and cardiac tamponade develop after antibiotic treatments or pericardiotomy. The diagnosis should be esablished by microbiologic or histologic identification of Candida in pericardial fluid or tissue. Treatment includes antifungal agents in combination with pericardiocentesis and operative drainage. Unless it is treated, Candida pericarditis is highly lethal, but prompt diagnosis and treatment result in a favorable outcome.
| Footnotes |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Soler-Soler and J. Sagrista-Sauleda CHAPTER 19 Pericardial Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
Task Force members, B. Maisch, P. M. Seferovic, A. D. Ristic, R. Erbel, R. Rienmuller, Y. Adler, W. Z. Tomkowski, G. Thiene, M. H. Yacoub, et al. Guidelines on the Diagnosis and Management of Pericardial Diseases Executive Summary: The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology Eur. Heart J., April 1, 2004; 25(7): 587 - 610. [Full Text] [PDF] |
||||
![]() |
P. G. Pappas, J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards Guidelines for Treatment of Candidiasis Clinical Infectious Diseases, January 15, 2004; 38(2): 161 - 189. [Full Text] [PDF] |
||||
![]() |
V. K. Kok, M. Y. Chu, Y. K. Wong, F. C. Lee, V. K. Kok, M. Y. Chu, Y. K. Wong, and F. C. Lee Successful Treatment of Candida Pericarditis Following Sternotomy Asian Cardiovasc Thorac Ann, December 1, 2000; 8(4): 384 - 386. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Rex, T. J. Walsh, J. D. Sobel, S. G. Filler, P. G. Pappas, W. E. Dismukes, and J. E. Edwards Practice Guidelines for the Treatment of Candidiasis Clinical Infectious Diseases, April 1, 2000; 30(4): 662 - 678. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |